Central and peripheral nervous system complications of COVID-19
a prospective tertiary center cohort with 3-month follow-up

Nersesjan, Vardan; Amiri, Moshgan; Lebech, Anne-Mette; Roed, Casper; Mens, Helene; Russell, Lene; Fonsmark, Lise; Berntsen, Marianne; Sigurdsson, Sigurdur Thor; Carlsen, Jonathan; Langkilde, Annika Reynberg; Martens, Pernille; Lund, Eva Løbner; Hansen, Klaus; Jespersen, Bo; Folke, Marie Norsker; Meden, Per; Hejl, Anne-Mette; Wamberg, Christian; Benros, Michael E; Kondziella, Daniel

Published in:
Journal of Neurology

DOI:
10.1007/s00415-020-10380-x

Publication date:
2021

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY

Citation for published version (APA):
Nersesjan, V., Amiri, M., Lebech, A-M., Roed, C., Mens, H., Russell, L., Fonsmark, L., Berntsen, M., Sigurdsson, S. T., Carlsen, J., Langkilde, A. R., Martens, P., Lund, E. L., Hansen, K., Jespersen, B., Folke, M. N., Meden, P., Hejl, A-M., Wamberg, C., ... Kondziella, D. (2021). Central and peripheral nervous system complications of COVID-19: a prospective tertiary center cohort with 3-month follow-up. Journal of Neurology, 268, 3086–3104. https://doi.org/10.1007/s00415-020-10380-x
Central and peripheral nervous system complications of COVID-19: a prospective tertiary center cohort with 3-month follow-up

Vardan Nersesjan1 · Moshgan Amiri1 · Anne-Mette Lebech2,12 · Casper Roed2 · Helene Mens2 · Lene Russell5 · Lise Fonsmark3 · Marianne Berntsen4 · Sigurdur Thor Sigurdsson4 · Jonathan Carlsen5 · Annika Reynberg Langkilde5 · Pernille Martens5 · Eva Løbner Lund6 · Klaus Hansen1 · Bo Jespersen7 · Marie Norsker Folke8 · Per Meden8 · Anne-Mette Hejl8 · Christian Wamberg9 · Michael E. Benros10,11 · Daniel Kondziella1,12

Received: 20 November 2020 / Revised: 18 December 2020 / Accepted: 19 December 2020 / Published online: 13 January 2021
© The Author(s) 2021

Abstract

Objective To systematically describe central (CNS) and peripheral (PNS) nervous system complications in hospitalized COVID-19 patients.

Methods We conducted a prospective, consecutive, observational study of adult patients from a tertiary referral center with confirmed COVID-19. All patients were screened daily for neurological and neuropsychiatric symptoms during admission and discharge. Three-month follow-up data were collected using electronic health records. We classified complications as caused by SARS-CoV-2 neurotropism, immune-mediated or critical illness-related.

Results From April to September 2020, we enrolled 61 consecutively admitted COVID-19 patients, 35 (57%) of whom required intensive care (ICU) management for respiratory failure. Forty-one CNS/PNS complications were identified in 28 of 61 (45.9%) patients and were more frequent in ICU compared to non-ICU patients. The most common CNS complication was encephalopathy (n = 19, 31.1%), which was severe in 13 patients (GCS ≤ 12), including 8 with akinetic mutism. Length of ICU admission was independently associated with encephalopathy (OR = 1.22). Other CNS complications included ischemic stroke, a biopsy-proven acute necrotizing encephalitis, and transverse myelitis. The most common PNS complication was critical illness polyneuromyopathy (13.1%), with prolonged ICU stay as independent predictor (OR = 1.14). Treatment-related PNS complications included meralgia paresthetica. Of 41 complications in total, 3 were para/post-infectious, 34 were secondary to critical illness or other causes, and 4 remained unresolved. Cerebrospinal fluid was negative for SARS-CoV-2 RNA in all 5 patients investigated.

Conclusion CNS and PNS complications were common in hospitalized COVID-19 patients, particularly in the ICU, and often attributable to critical illness. When COVID-19 was the primary cause for neurological disease, no signs of viral neurotropism were detected, but laboratory changes suggested autoimmune-mediated mechanisms.

Keywords COVID-19 · SARS-COV-2 · Coronavirus · Critical illness · Encephalopathy · Myelitis

Introduction

Central (CNS) and peripheral (PNS) nervous system manifestations can occur during and after coronavirus disease 2019 (COVID-19) [1–6], but the underlying mechanisms, the semiology and the frequency of these complications remain poorly understood [7, 8].

Limited postmortem studies have shown signs of hypoxic brain injury [9] and neuro-inflammatory changes in the brainstem [10], while neuropathological data from the PNS are so far almost non-existent. As to the etiology, direct...
invasion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into neuronal tissue has been suggested in a few cases [11, 12], but autoimmune-mediated injury and neurological complications related to intensive care management are also recognized [7, 8]. The contribution of these mechanisms to the overall burden of COVID-19 CNS and PNS complications is unknown. Furthermore, the reported prevalence of these complications varies widely, from 3.5 to 84% [1–6], owing to the heterogeneity in methodology and case definitions. Some reports include descriptions of neurological symptoms but no confirmatory laboratory investigations, which makes the distinction between primary COVID-19- and secondary critical illness-induced complications difficult [5]. For instance, more than one half of patients with sepsis show signs of sepsis-associated encephalopathy [13] and a further 70% of those with sepsis-associated encephalopathy develop critical illness polyneuromyopathy (CIPM) [14]. Also, many studies report on observations made during neurological consultation, thereby missing cases that are not referred to a neurologist [15]. Finally, most reports include convenience samples, lack follow-up and do not attempt to determine if COVID-19 complications are caused by direct viral invasion of the nervous system, by para/post-infectious immune-mediated mechanisms or by treatment-related injury [7, 16].

Here, we conducted a prospective observational study of a complete and consecutive sample of COVID-19 patients from a tertiary referral center, including 3-month follow-up. Our aim was to describe the frequency and phenomenology of CNS and PNS complications, as well as their presumed origin as determined by neurological work-up, during and after SARS-CoV-2 infection. The primary endpoints were the number, clinical phenotypes and disease mechanisms of patients with COVID-19-related CNS and PNS complications compared to all patients admitted with COVID-19. We hypothesized that these complications would be more frequent and serious in the most severely affected COVID-19 patients and that immune-mediated and treatment-related complications would be more prevalent than those related to SARS-CoV-2 neurotropism.

Methods

Study population

From April to September 2020, we prospectively enrolled SARS-CoV-2-positive patients ≥ 18 years of age, admitted to Rigshospitalet, Copenhagen University Hospital, a tertiary referral center in Copenhagen, Denmark. Patients were enrolled from the hospital’s newly established COVID-19 intensive care unit (COVITA), the COVID-19 intermediate care unit (COVIMA) and the neurological department. Two of the authors (VN, MA), supervised by a board-certified neurologist with experience in neurocritical care (DK), screened all three departments each morning for newly admitted patients with COVID-19. All included patients had positive SARS-CoV-2 polymerase chain reaction (PCR) by nasopharyngeal/tracheal testing, except for 1 patient in whom a clinical suspicion of COVID-19 was confirmed 27 days after symptom onset by a strongly positive SARS-CoV-2 IgG antibody titer. We followed all patients prospectively from the time of enrollment to discharge and 3-month follow-up or death. Patients were prospectively screened for neurological and psychiatric symptoms during admissions at COVITA and COVIMA and evaluated for cognitive status and neurological deficits at discharge. Patients enrolled from the neurological department were screened for suspected neurological complications during/after a COVID-19 infection.

Clinical screening during admission

We used a pre-specified screening tool made to detect neurological and psychiatric symptoms (see appendix, Fig. S1) during admission at COVITA and COVIMA. The screening tool was incorporated as part of the daily clinical rounds by the attending physicians, and patients were examined systematically at the bedside to detect CNS and PNS symptoms and/or deficits. Each day, all COVID-19 patients were thus screened for the following:

I. Consciousness level as assessed by Glasgow Coma Scale (GCS) and Full-Outline of UnResponsiveness (FOUR) scores. When appropriate, sedated ICU patients were assessed following a wake-up call and categorized as showing either ‘rapid recovery’, ‘slow awakening’ (defined as prolonged recovery following ≥ 24 h clinical unresponsiveness after stop of sedation) and ‘no awakening’ (defined as coma or vegetative state/unresponsive wakefulness syndrome persisting for ≥ 24 h).

II. Complaints of headache and somatosensory symptoms, i.e. anosmia and/or ageusia, pain, and paresthesia.

III. Cognitive deficits, motor palsy, sensory deficits, cranial nerve deficits and cerebellar affection (e.g. ataxia or nystagmus) as determined by clinical neurological exam.

IV. Seizures, irrespective of supposed origin (i.e. epileptic versus non-epileptic).

V. Presence of delirium, defined as presence of auditory or visual hallucinations, delusional thoughts, such as paranoia, psychomotor agitation or reduction and/or fluctuating consciousness with disorientation.
VI. Emotional lability defined as exaggerated or uncontrollable laughing, crying or anger disproportionate to the circumstances.

Further, we collected routine clinical and laboratory data including age, sex, medication, previous medical history, and results from brain imaging (CT or MRI) during admission, cerebrospinal fluid (CSF) results, electroencephalography (EEG) findings, nerve conduction studies (ENG) and electromyography (EMG), as well as modified Rankin Scale (mRS) prior to admission, at discharge and at 3-month follow-up.

Two board-certified neuroradiologists systematically re-evaluated all clinical neuroimaging (if present) of all enrolled patients during admission and after discharge, including CT, CT angiography and MRI, according to a pre-specified protocol, classifying burden, localization, and (possible) etiology of acute and chronic (i.e. unrelated to the present admission) pathologies.

Discharge evaluation

At discharge (i.e. 0–4 days prior to discharge), we evaluated patients with a full neurological exam, including the Montreal Cognitive Assessment (MOCA). When a full MOCA was not possible (e.g. owing to the patient’s lack of English or Danish language proficiency), we examined with a clock-drawing test to assess executive function [17] and search for hemi-spatial neglect, and a simple 5 min 3-word recall test to assess memory function. Gait function was categorized as normal, assisted or bedridden/wheelchair.

Three-month follow-up

Enrolled patients were followed up 3 months after discharge via electronic health records (EHR). We obtained follow-up data on mRS, re-admissions (if any), death after discharge, and new-onset neurological and psychiatric diagnoses. If mRS data were not available from the EHR, we obtained the data via telephone interview with the patient or next-of-kin.

Pre-specified complications

Based on our observed findings, we screened for the following pre-specified CNS and PNS complications occurring during admission or after discharge and 3-month follow-up:

CNS: (a) stroke (i.e. ischemic or hemorrhagic, or subarachnoid hemorrhage); (b) encephalopathy [18], i.e. change in personality, behavior, cognition or consciousness, including delirium; and categorized as “mild”, when behavioral and/or cognitive changes occurred without reduced consciousness (GCS ≥ 13), or “severe” (all other), and reduced consciousness was only noted when patients were off sedation; (c) encephalitis [19], i.e. encephalopathy PLUS new focal CNS deficits and/or new-onset epileptic seizures PLUS CSF inflammation (e.g. pleocytosis) and/or MRI changes and/or brain pathology suggesting brain inflammation; (d) myelitis, i.e. clinical signs of medullary affection and MRI confirmed changes suggesting inflammatory lesions; and (e) primary psychiatric disorders, including depression, anxiety, post-traumatic stress disorder, obsessive compulsive disorder or psychotic disorder diagnosed by ICD-10 criteria.

PNS: (a) neuropathies, including mono- (e.g. peripheral facial palsy) and polyneuropathies (e.g. Guillain–Barré syndrome); (b) acute myopathies, defined as myalgia with motor paresis and biochemical evidence of muscle degradation (e.g. elevated creatine kinase or myoglobin at least 5 times the upper limit of normal) [20]; and (c) CIPM, i.e. defined as limb weakness with clinical signs of lower sensory and motor neuron deficits following sepsis, multi-organ failure, respiratory failure, and/or septic inflammatory response syndrome; categorized as ‘definite’ with consistent ENG/EMG abnormalities or ‘possible’ without neurophysiological exam.

Case definitions of SARS-CoV-2-associated neurological disease

Based on the recently proposed case definition of neurological complications owing to COVID-19 [10], we assigned the observed complications to one of the following disease mechanisms:

A. Direct viral invasion. (1) Evidence of SARS-CoV-2 detected in CSF or evidence of SARS-CoV-2-specific intrathecal antibody production; and (2) no other explanatory pathogen or cause found.

B. Immune-mediated mechanisms. (1) Neurological disease onset within 6 weeks of acute infection; (2) no evidence of other commonly associated causes (e.g. recently or concomitant infection with campylobacter, cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex (HSV) or varicella virus (VZV)) and (3) paraclinical evidence of immune-mediated mechanisms, such as inflammatory lesions on MRI and/or CSF pleocytosis or oligoclonal bands and/or brain pathology findings.

C. Complications secondary to critical illness, management-related or other causes. (1) Other, more likely causes, such as delirium, hypoxia, sepsis, metabolic derangement or other complications to critical illness (e.g. septic or hypoxic encephalopathy), and (2) if investigated with brain imaging, EEG or CSF study, there are no signs of disease mechanism A or B.

D. Insufficiently investigated. (1) No explainable cause found, therefore not categorized as C, and (2) not inves-
tigated with relevant CSF study and/or neuroimaging to confirm or dismiss A or B disease mechanisms.

Patients were classified in the case definitions by two observers (VN, MA) with >4 years neurological experience based on consensus. Disagreement was settled by a third observer (DK) with >15 years of neurological experience.

Statistical analysis

Based on the data from clinical screening during admission (2.2) and at 3-month follow-up (2.4), we assessed if patients had developed CNS or PNS complications and categorized these complications as having occurred ‘during admission’ or ‘after admission’, i.e. patients who were not admitted for an active SARS-CoV2 infection but admitted for a neurological complication following COVID-19 were categorized as ‘after admission’. Patients were dichotomized in ICU and non-ICU admission and demographic variables, neurological and neuropsychiatric symptoms during admission and discharge, paraclinical findings and 3-month follow-up characteristics were compared using the student’s $t$ test for normally distributed values, the Mann–Whitney $U$ test (Wilcoxon rank-sum) for non-normally distributed continuous variables and Fisher’s exact test for categorical values. Variables for binary logistic regression for the development of severe encephalopathy or CIPM were selected based on biological plausibility and bivariate associations seen in our data. A 2-sided $p < 0.05$ was considered significant. We did not correct for multiple testing. All analyses were performed using Stata/IC 15.1 (StataCorp. 2017, College Station, TX).

Ethics statement

The Ethics Committee of the Capital Region of Denmark approved the study and waived the need for written consent because the risks were deemed negligible (reference j.nr. 20025838).

Results

From April 1 to September 25, 2020, we prospectively enrolled 61 COVID-19 patients ≥ 18 years, consecutively admitted to Rigshospitalet, Copenhagen University Hospital. Mean age was 62.7 years, and the male-to-female ratio was 1.7:1 (63% males). Prior to COVID-19, somatic comorbidities were known in 52 (85%), neurological comorbidities in 11 (18%) and psychiatric comorbidities in 4 (6.6%) of the 61 patients. Mean days from COVID-19 symptom onset to hospital admission were 7.2, and mean admission duration was 29.7 days. Seventeen patients (27.9%) were treated with renal replacement therapy and 35 patients (57.4%) were admitted to the ICU, of which 34 (97%) were mechanically ventilated (21 in the prone position, 61.7%) and 6 (17.1%) treated with extracorporeal membrane oxygenation (ECMO). Ten (16.4%) patients died in-hospital, and 3-month follow-up was available for 45 patients. See Table 1 for full outline of basic demographics including previous medical history and admission characteristics, and Fig. 1 for an overview over patient enrollment and observed complications. In the following, results are listed according to symptoms (Tables 2, 3, 4), investigations (Fig. 2 and Table 5) and clinical diagnoses (Table 6).

Clinical screening during admission

Neurological symptoms

The most common neurological finding was motor weakness seen in 21 patients (34.4%) which was significantly more prevalent in ICU patients (54%) compared to non-ICU patients (7.7%), $p = 0.002$. The second most common finding was anosmia and/or ageusia in 18 patients (29.5%), significantly more prevalent in non-ICU patients (46.2%) compared to ICU patients (17.1%), $p = 0.02$. Ten patients (16.4%) complained of headache and 3 (4.9%) of sensory symptoms, which were not attributable to a specific cause. Seizures were observed in 3 patients (4.9%), including epileptic seizures in 2 of these patients (generalized tonic–clonic seizures), and non-epileptic seizures in 1 patient with dystonic painful contractions/seizures in the right hand lasting 10–20 s every day for 6 days. Unfortunately, no brain imaging or EEG was performed in the latter patient because he deteriorated in respiratory function and died in the ICU.

Of the 35 ICU-admitted patients, 9 (26.4%) had prolonged awakening from sedation and clinical unresponsiveness in >24 h, resulting in EEG investigations in 7 patients. Two patients (5.9%) were in prolonged coma off sedation, resulting in death due to withdrawal of life-supporting therapy following discussions with the families.

Neuropsychiatric symptoms

A total of 21 (34.4%) patients had delirium during admission lasting 7.1 days (mean, standard deviation (SD) 6.9), which was significantly more frequent in ICU-patients (54.3%) compared to non-ICU patients (7.7%), $p < 0.001$. The most common finding in delirious patients was hallucinations (12 patients, 20.3%), and the most frequent motor subtype of delirium was hypokinetic delirium (13 of 21 patients, 61.9%). Table 2 shows a full outline of CNS and PNS symptoms during admission.
| Demographics                        | All             | No ICU admission | ICU admission | p value |
|------------------------------------|-----------------|------------------|---------------|---------|
| Total population, N (%)           | 61 100%         | 26 42.6%         | 35 57.4%      | 0.56    |
| Age, years, mean (SD)              | 62.7 13.8       | 63.4 17.8        | 61.2 11.4     | 0.52    |
| Male, N (%)                        | 38 63.3%        | 15 58.0%         | 23 66.7%      | 0.52    |
| Female, N (%)                      | 23 37.7%        | 11 42.0%         | 12 34.3%      | 0.52    |
| BMI, median (IQR)                  | 25.5 22–32      | 24 20–30         | 27 23–32      | 0.14    |
| BMI > 26, N (%)                    | 31 50.0%        | 11 42.0%         | 20 57.1%      | 0.32    |
| mRS at admission, median (IQR)     | 0 0–1           | 1 0–2            | 0 0–1         | 0.07    |
| Ethnicity, N (%)                   |                 |                  |               | 0.04    |
| Caucasian                          | 49 80.3%        | 21 81.0%         | 28 80.0%      |         |
| Asian                              | 2 3.3%          | 0 0.0%           | 2 5.7%        |         |
| Middle Eastern                     | 2 3.3%          | 1 4.0%           | 1 2.9%        |         |
| African                            | 4 6.7%          | 0 0.0%           | 4 11.4%       |         |
| Inuit                              | 4 6.7%          | 4 15.0%          | 0 0.0%        |         |
| Past medical history               |                 |                  |               |         |
| Somatic comorbidities, any, N (%)  | 52 85.2%        | 24 92.0%         | 28 80.0%      | 0.18    |
| Hypertension                       | 15 24.6%        | 7 26.9%          | 8 22.9%       | 0.72    |
| Hyperlipidemia                     | 5 8.2%          | 3 11.5%          | 2 5.7%        | 0.41    |
| Diabetes type 2                    | 9 14.8%         | 2 7.7%           | 7 20.0%       | 0.18    |
| Ischemic heart disease             | 8 13.1%         | 2 7.7%           | 6 17.1%       | 0.28    |
| Atrial fibrillation                | 8 13.1%         | 3 11.5%          | 5 14.3%       | 0.75    |
| Heart failure                      | 3 4.9%          | 1 3.8%           | 2 5.7%        | 0.74    |
| Asthma                             | 3 4.9%          | 0 0.0%           | 3 8.6%        | 0.13    |
| COPD                               | 5 8.2%          | 3 11.5%          | 2 5.7%        | 0.41    |
| Interstitial lung disease          | 1 1.6%          | 0 0.0%           | 1 2.9%        | 0.38    |
| Nephropathy                        | 9 14.8%         | 5 19.2%          | 4 11.4%       | 0.40    |
| Malignancy, organ                  | 5 8.2%          | 4 15.4%          | 1 2.9%        | 0.07    |
| Malignancy, hematological          | 10 16.4%        | 6 23.1%          | 4 11.4%       | 0.07    |
| Autoimmune disease                 | 6 9.8%          | 3 11.5%          | 3 8.6%        | 0.70    |
| Liver cirrhosis                    | 1 1.6%          | 1 3.8%           | 0 0.0%        | 0.24    |
| Chronic infection\(^d\)            | 2 3.3%          | 1 3.8%           | 1 2.9%        | 0.35    |
| Major surgery within a year        | 6 9.8%          | 2 7.7%           | 4 11.4%       | 0.63    |
| Other                              | 6 9.8%          | 1 3.8%           | 5 14.3%       | 0.18    |
| Neurological comorbidities, any, N (%)\(^f\) | 11 18.0%        | 5 19.2%          | 6 17.1%       | 0.83    |
| Stroke                             | 3 4.9%          | 1 3.8%           | 2 5.7%        | 0.67    |
| Epilepsy                           | 1 1.6%          | 0 0.0%           | 1 2.9%        | 0.38    |
| Dementia or MCI                    | 1 1.6%          | 1 3.8%           | 0 0.0%        | 0.24    |
| Primary headache                   | 2 3.3%          | 0 0.0%           | 2 5.7%        | 0.46    |
| Neuromuscular                      | 1 1.6%          | 1 3.8%           | 0 0.0%        | 0.24    |
| Other                              | 4 6.6%          | 2 7.7%           | 2 5.7%        | 0.76    |
| Psychiatric comorbidities, any, N (%)\(^f\) | 4 6.6%          | 1 3.8%           | 3 8.6%        | 0.46    |
| Depression                         | 4 6.6%          | 1 3.8%           | 3 8.6%        | 0.46    |
| PTSD                               | 1 1.6%          | 0 0.0%           | 1 2.9%        | 0.38    |
| Immunosuppression, N (%)           | 14 23.0%        | 9 34.6%          | 5 14.3%       | 0.15    |

\(^a\) All compared to No ICU admission, \(^b\) All compared to ICU admission, \(^c\) Comparing No ICU admission to ICU admission, \(^d\) AIDS, or another immunosuppressive agent, \(^f\) Any neurological or psychiatric comorbidity.
Laboratory investigations

During admission, CT was performed in 16 patients (26.2%), MRI in 7 patients (11.4%), EEG in 12 patients (19.7%), and CSF was investigated in 8 patients (13.1%). ICU-admitted patients were more frequently investigated with EEG than non-ICU patients (28.6% vs. 7.7%, \(p = 0.04\)), and the most common findings were compatible with an encephalopathic curve, i.e. background slowing including increased theta and delta activity, seen in 50% of all the investigated patients, and frontal intermittent rhythmic delta activity (FIRDA) seen in 40% of the investigated patients. Of 8 patients who had CSF investigations during the study period, 3 patients had pleocytosis (cell count > 5 cells/microl): In one patient with severe headache and respiratory failure, a lumbar puncture showed 13 cells/microl with negative VZV-PCR but intrathecal production of varicella zoster IgG antibodies; CSF SARS-CoV-2 PCR was not performed. The other 2 patients with CSF pleocytosis had myelitis and encephalitis (see 3.4 for details). Five of the 8 CSF samples were tested for SARS-CoV-2 RNA (all negative), and one of the 8 CSF samples was tested for SARS-CoV-2 antibodies which were found positive (Fig. 3b). For full outline of paraclinical findings, see Table 5 and Fig. 2.

Clinical screening at discharge

Of the 61 patients, 53 (86.9%) were examined at discharge with a full neurological exam, including cognitive screening for amnesia, dysexecutive function, apraxia, aphasia and neglect; and 32 patients (52.5%) were examined with a MOCA. As already stated, 10 patients died during their hospital stay (16.4%).

Neurological symptoms

We observed tetraparesis with hyporeflexia and muscle atrophy in 8/53 (15%) and gait impairment categorized as
bedridden/wheelchair in 12/53 (22.6%) patients, which both were significantly more frequent in ICU patients, $p = 0.002$ and $p = 0.001$, respectively. Median MOCA score was 22 in the total population, but lower in patients admitted to the ICU (median 19.5) than in non-ICU patients (median 25), $p$ value = 0.02. Median mRS at discharge was 3 (IQR 2–5). See Table 3 for full data on discharge evaluation.

**Neuropsychiatric symptoms**

Amnesia ($n = 18/53$, 34.0%) and dysexecutive function (20/53, 37.7%) were the most common cognitive deficits and more prevalent in ICU patients compared to non-ICU patients, $p = 0.01$ and $p < 0.001$, respectively.

**Follow-up after 3-month**

Three-month follow-up data were available for 45 patients (Table 4). The median 3-month mRS was 1 (IQR 1–2), which was not significantly different between ICU-admitted ($mRS = 1$, IQR: 0.5–2.5) and the remaining patients ($mRS = 1$, IQR: 1–2). Seventeen patients (37.8%) were re-hospitalized after discharge, and 4 of these (23.5%) were re-hospitalized at a neurological department: One patient had a new-onset ischemic stroke; 1 had recurrent generalized tonic–clonic seizures due to hypomagnesemia secondary to a refeeding syndrome; 1 had memory decline and gait difficulties with brain MRI showing normal pressure hydrocephalus; and finally, 1 patient had new-onset mild dysphagia, tongue palsy and a right-sided drop foot, compatible with hypoglossal and peroneal nerve injuries, investigated with a brain MRI with normal findings and ENG showing bilateral mild peroneal nerve affection; symptoms resolved spontaneously after 3 weeks. Follow-up data were missing for 16 patients (10 deaths, 6 patients with less than 3-month follow-up).

**CNS complications**

A total of 19 patients (31.1%) had signs of encephalopathy at some stage during their admission, and 13 (68.4%) of those were categorized as having severe encephalopathy (GCS 12 or less). Patients with severe encephalopathy had significantly longer hospital stays (median 21 vs. 44 days without encephalopathy, $p < 0.001$), required more often treatment with haloperidol (61.5% vs. 16.7% with less severe encephalopathy, $p = 0.03$) and were more often admitted to the ICU (80% vs. 50% of all patients, $p = 0.04$). Among the 13 patients with severe encephalopathy, we encountered 8 patients who were apathetic and severely hypokinetic/akineti
c, with almost no voluntary movements and without any verbal output, yet they were able to follow the examiner with the eyes and indicate yes and no to questions by nodding or shaking their heads. On examination, all these patients had a palmomental reflex. This state of akinetic mutism lasted for a median of 4 days (IQR 2.5–6.5). Seven of the 8 patients with akinetic mutism had been admitted to the ICU, 5 required dialysis for renal failure, 4 were treated with haloperidol for delirium, 3 had FIRDA on EEG, 1 had multiregional sharp waves on EEG, and 1 patient had a non-traumatic cortical subarachnoid bleed in the right frontal lobe. The most likely cause for mild encephalopathy was delirium. In 13 patients with severe encephalopathy, the most likely causes were septic/toxic encephalopathy in 10, metabolic encephalopathy in 1 and multifactorial delirium in 2 patients.

Two patients were diagnosed as having encephalitis. One patient, previously healthy, was admitted with generalized epileptic seizures 10 days after onset of fever, dry cough and myalgia and a strongly positive IgG antibody response to SARS-CoV-2 (Fig. 3a). Brain MRI showed bilateral basal ganglia inflammatory lesions with hemorrhagic transformation, and CSF showed normal cell and protein count; CSF SARS-CoV-2 PCR was negative. A brain biopsy was obtained to rule out a brain abscess, but investigations for a microbiological, fungal or neoplastic etiology were negative. Biopsy showed multiple fibrinous thrombosis in the microvasculature in keeping with a histological diagnosis of hemorrhagic necrotizing encephalitis. The patient was diagnosed as having COVID-19-associated acute necrotizing encephalitis and referred for neurorehabilitation.

The second patient with encephalitis had a medical history of kidney transplantation and immunosuppression and...
was admitted due to myalgia and a dry cough with a positive SARS-CoV-2 PCR on pharyngeal swab and, 11 days later, developed severe apathy, amnesia and initially mild aphasia but no other focal deficits (Fig. 3c). Brain MRI showed multiple ischemic lesions bilaterally in the basal ganglia, thalami, juxtacortical white matter and in the right side of the pons. CSF analysis revealed lymphocytic pleocytosis (250 cells/microl), and microbiological screening showed positive EBV, HSV-1 and VZV DNA copies (which the attending microbiologist concluded was reactive and associated with chronic immunosuppressive therapy). SARS-CoV-2 PCR on CSF material was negative, but SARS-CoV-2 antibodies were positive in the CSF. The patient was discharged to neurorehabilitation and improved slowly with a decline in CSF cell count on follow-up without specific treatment.

One patient developed lumbar pain, thoracic numbness with a sensory level at T5, urinary retention and mild paraparesis 13 days after COVID-19 symptom onset with myalgia and fever, and 6 days after remission of COVID-19 symptoms (Fig. 3b). Spinal MRI showed transverse myelitis, CSF analysis revealed 125 lymphocytic cells/microl, and microbiological screening including SARS-CoV-2 PCR was negative. The patient made an uneventful recovery following steroid treatment and plasma exchange.

We used a logistic regression model with the covariates age, sex, number of admission days, number of days in the ICU, dialysis, delirium, and treatment with haloperidol. Duration of ICU admission was independently associated with severe encephalopathy with OR = 1.22 (95% CI 1.02–1.43; \( p = 0.03 \)).

PNS complications

During admission, we observed 9 (13.1%) patients with PNS complications. Eight patients were tetraparetic at discharge, had muscle atrophy and hyporeflexia, and all had
been admitted to the ICU. One of these 8 patients was investigated with ENG/EMG and diagnosed with definite CIPM, the remainder were categorized as having possible CIPM. All 8 patients with definite or possible CIPM, when compared to patients without neuromuscular complications, had significantly longer admissions (median 49.5 vs. 23 days, \( p < 0.001 \)), were more frequently admitted to the ICU (100% vs. 40%, \( p = 0.002 \)), more often treated with renal replacement therapy (62% vs. 14%, \( p = 0.008 \)), and were more often delirious (75% vs. 30%, \( p = 0.02 \)).

Further, one patient was admitted with rhabdomyolysis and kidney failure with a peak creatine kinase of 74,000 Units/L. Following symptomatic treatment including forced diuresis, the patient was discharged with proximal paraparesis to rehabilitation with a diagnosis of acute myopathy.

From discharge to 3-month follow-up, we observed 4 patients with PNS complications. Two ICU patients complained of burning paranesthesia and numbness of the lateral thigh (bilaterally in one case) and were diagnosed as having meralgia paresthetica. Both patients had been ventilated in the prone position leading to compression of the lateral femoral cutaneous nerve. Two patients developed a peripheral facial palsy after discharge. One patient had a right-sided palsy together with a cutaneous rash in the neck 3 months after a positive SARS-CoV-2 test, and microbiological cultures and antibody tests of the skin lesion confirmed varicella zoster virus infection.
(VZV). The CSF was notable for a marginal pleocytosis of 7, protein of 0.7 g/L, negative borrelia, VZV, herpes simplex virus, enterovirus screening and negative CXCL-13. The second patient developed peripheral facial palsy 40 days after a positive SARS-CoV-2 test; there were < 3 cells in the CSF, protein was 0.16 g/L, and screening for herpes simplex virus, VZV, Epstein–Barr virus and cultures were negative. Neither of the patients’ CSF specimens were screened for SARS-CoV-2.

One patient was seen 5 weeks after discharge with a right-sided foot drop, mild dysphagia and a tongue palsy deviating to the left. Brain MRI was unremarkable, and ENG showed mild bilateral peroneal nerve affection. Symptoms resolved spontaneously after 2 weeks. CSF was not investigated.

We used a logistic regression model with the covariates of total admission days, dialysis, delirium, ICU admission and age, and found that the duration of admission was an independent risk factor for (possible) CIPM with an increase of OR = 1.14 (95% CI 1.00–1.32) for each day of admission, \( p = 0.046 \).

### Case definitions

The observed complications were classified in 4 different groups based on a case definition approach described in methods.

No complications met criteria for ‘direct viral invasion’ (A), 3 complications met criteria for ‘immune-mediated mechanisms’ (B), 34 complications were categorized as ‘complications secondary to critical illness, management-related or other causes’ (C) and 4 complications which could

| Discharge evaluationa | All, \( N = 61 \) | No ICU admission, \( N = 26 \) | ICU admission, \( N = 35 \) | \( p \) value |
|-----------------------|-----------------|-----------------|-----------------|------------|
| \( N \) %/IQR | \( N \) %/IQR | \( N \) %/IQR | \( p \) value |
| In-hospital death, \( N \) (%) | 10 16.4 1 3.8 9 25.7 | 0.017 |
| MRAS at discharge, median (IQR) | 3 2–5 2 1–3 4 4–6 | < 0.001 |
| MOCA test performed, \( N \) (%) | 32 52.5 18 69.2 14 40.0 | 0.03 |
| MOCA score, median (IQR) | 22 18.5–28 25 22–29 19.5 16–24 | 0.02 |
| Full neurological examination performed, \( N \) (%)b | 53 86.9 26 100 27 77.1 | |
| Neurological deficits at discharge, \( N \) (%)c | |
| Cognitive | |
| Amnestic | 18 34.0 5 19.2 13 48.1 | 0.01 |
| Aphasia | 2 3.8 0 0.0 2 7.4 | 0.12 |
| Apraxia | 4 7.5 2 7.7 2 7.4 | 0.9 |
| Dysexecutive | 20 37.7 5 19.2 15 55.6 | 0.001 |
| Neglect | 0 0.0 0 0.0 0 0.0 | |
| Motor and gait | |
| Hemiparesis | 2 3.8 1 3.8 1 3.7 | – |
| Paraparesis | 2 3.8 1 3.8 1 3.7 | – |
| Tetraparesis | 11 20.8 0 0.0 11 40.7 | < 0.001 |
| Tetraparesis with hyporeflexia and atrophy | 8 15.1 0 0.0 8 29.6 | 0.002 |
| Generalized weakness | 6 11.3 1 3.8 5 18.5 | – |
| Gait impairment, assisted with walking device | 11 20.8 5 19.2 6 22.2 | – |
| Gait impairment, bedridden/wheelchair | 12 22.6 1 3.8 11 40.7 | 0.001 |
| Ataxia and/or dysmetric coordination | 7 13.2 0 0.0 7 25.9 | 0.02 |
| Dysartrhia and/or dysphagia | 3 5.7 0 0.0 3 11.1 | 0.16 |

Discharge evaluation of COVID-19 positive patients dichotomized in ICU and non-ICU patients

**ICU** intensive care unit, **mRS** modified rankin scale, **IQR** inter quartile range, **MOCA** montreal cognitive assessment

\( a \)For categorical values we tested with Fisher’s exact test; for normal distributed values we used a student’s \( t \) test and for non-normal distributed values we calculated median and tested with non-parametric test for \( p \) value

\( b \)Patients who died during heavy sedation or were transferred to other ICU at different hospitals were not examined at discharge

\( c \)One patient may have several deficits
Discussion

In this prospective study of consecutively enrolled hospitalized COVID-19 patients, half of which were admitted to the ICU, we evaluated the semiology, frequency and cause of CNS and PNS complications of COVID-19 during admission and at discharge. In addition, we collected 3-month follow-up data using EHR. As hypothesized, CNS and PNS complications were immune-mediated or treatment-related and more frequent and serious in COVID-19 patients requiring ICU management. Overall, we identified 41 neurological complications in 28 of 61 patients (46%). The most common CNS complication was encephalopathy, which we encountered in roughly one third of all COVID-19 patients and which was associated with the length of ICU admission. The most common PNS complication was CIPM, seen in 13% of patients, again with length of admission as an independent predictor. After applying our case criteria described in methods, only 3 observed complications met criteria for SARS-CoV-2-associated immune-mediated neurological disease: 2 encephalitides and 1 myelitis. All other complications were classified as either secondary to critical illness or other causes or were insufficiently investigated.

Encephalopathy

Encephalopathy affected roughly a third of COVID-19 patients, which is consistent with a recent retrospective study [21], yet considerably lower than previous reports from the early phase of the pandemic (69%) [1], and much higher than another, prospective recent report (6.8%) [15]. This probably reflects differences in methodology as outlined below. Interestingly, we encountered 8 patients with akinetic mutism, i.e. they were apathetic and profoundly hypokinetic with almost no voluntary movements and without any verbal output, although they were able to indicate yes and no by nodding with their heads when spoken to. On neurological exam, all these patients had some frontal release signs (e.g. palmomentum reflexes), and during our systematic daily clinical evaluation, we found this to be a transient phenomenon lasting for a median of 4 days. Akinetic mutism has been described in a COVID-19 case report, lasting 5 days [22], and in a case series of 4 patients [23], all 5 patients had frontal FDG-PET hypometabolism, while CSF and MRI findings were normal [22, 23]. Akinetic mutism is typically associated with frontal lobe injury [24], and we indeed observed frontal lobe abnormalities, including a small frontal lobe cortical subarachnoid hemorrhage in one patient and FIRDA in 3 of 4 patients investigated with EEG, while MRI in 3 and CSF in 2 patients were unremarkable. Seven of our 8 patients had long ICU admissions (median 21 days) and sepsis with multiorgan injury, and all had delirium. Indeed, hypokinetic delirium, which has clinical similarities to akinetic mutism, is the most frequent motor subtype of delirium [25], and brain FDG-PET of delirious patients may show cortical hypometabolism, most frequently in the frontal lobes [26].

Encephalitis and myelitis

We observed 3 cases of CNS inflammation compatible with para- or post-infectious immune-mediated complications to

---

Table 4  Follow-up at 3 months

|                        | All, N=45b | No ICU admission, N=21 | ICU admission, N=24 | p value |
|------------------------|------------|------------------------|---------------------|---------|
|                        | N %/IQR    | N %/IQR                | N %/IQR             |         |
| Death after discharge, N (%) | 2 4.4     | 2 9.5                  | 0 0                 | 0.12    |
| Hospitalization after discharge total, N (%) | 17 37.8 | 9 42.9                | 8 33.3              | 0.04    |
| Neurological department | 4 23.5     | 0 0                   | 4 50                | –       |
| Psychiatric department  | 0 0        | 0 0                   | 0 0                 | –       |
| Other                  | 13 76.5    | 9 100                 | 4 50                | –       |
| 3-month mRS, median (IQR) | 1 1–2     | 1 1–2                 | 1 0.5–2.5           | 1.00    |

Follow-up data 3 months after discharge of COVID-19 positive patients dichotomized in ICU and non-ICU patients

mRS modified rankin scale, IQR Inter quartile range, ICU intensive care unit

*For categorical values we tested with Fisher’s exact test; for normal distributed values we used a student’s t test and for non-normal distributed values we calculated median and tested with non-parametric test for p value

bFollow-up data on 45 patients. Ten patients died during admission; 6 patients still not passed 3 months after discharge

---

not be categorized as A, B or C were labeled ‘insufficiently investigated’ (D).
COVID-19 (Fig. 3). One patient was diagnosed with probable COVID-19-associated acute necrotizing encephalitis, after extensive laboratory evaluation including a brain biopsy and a whole-body FDG-PET ruled out other microbiological, autoimmune or neoplastic causes. Three previous cases of acute necrotizing encephalitis have been reported with COVID-19 [27–29]. All 3 patients, like ours, were females aged 30 to 40 years with neurological symptoms within 2 weeks of COVID-19 onset. Two cases [27, 28] were believed to be caused by an indirect immune-mediated hyperinflammation (i.e. a cytokine storm) [30], which also has been reported with other viral infections including influenza [31, 32], whereas in the third case [29], low levels of SARS-CoV-2 RNA were detected in the CSF indicating possibly direct viral neuronal injury.

Our second encephalitis patient had negative SARS-CoV-2 PCR but positive SARS-CoV-2 antibody testing in CSF. Given the pleocytosis of 250 cells, a protein of 1.13 g/L and a negative viral PCR, a plausible explanation for the positive antibody test would be blood contamination due to a leaky blood–brain-barrier and not direct viral invasion. Patients with neurological symptoms and positive SARS-CoV-2 PCR in CSF samples have been reported [11, 12], but the majority of patients with neurological manifestations investigated with PCR on CSF had undetected levels of SARS-CoV-2 [8]. This was consistent with our finding that all 5 CSF samples investigated for SARS-CoV-2 were PCR-negative.

Our third case of probable immune-mediated CNS inflammation was a patient with monophasic myelitis who made an uneventful recovery, with neurological symptom onset within 14 days after COVID-19 symptom debut and negative SARS-CoV-2 CSF PCR. As in another reported case [33], investigations for other causes of myelitis were
Table 5  Laboratory findings

|                  | All, N=61 | No ICU admission, N=26 | ICU admission, N=35 | p value |
|------------------|-----------|------------------------|---------------------|---------|
|                  | N %/IQR   | N %/IQR                | N %/IQR             |         |
| CT Brain performed, N (%) |          |                        |                     |         |
| CT Brain findings, N (%) |          |                        |                     |         |
| Normal or slight atrophy | 7 42.9 0.00 7 54.5 | 3 21.4 1 25.0 2 18.2 | -         | 0.08    |
| Old stroke       | 1 7.1 1 25.0 0 0.0 | -                      | -                  | 0.09    |
| Leukoaraiosis    | 1 7.1 0 0.0 3 1 1 100 | -                      | -                  | -       |
| New stroke       | 1 7.1 1 25.0 0 0.0 | -                      | -                  | -       |
| Hemorrhagic stroke | 1 7.1 0 0.0 1b 9.1 | -                      | -                  | -       |
| Superficial siderosis/subarachnoid bleed | 1 7.1 0 0.0 1 9.1 | -                      | -                  | -       |
| Other            | 2 14.2 1 25.0 1 9.1 | -                      | -                  | -       |
| MRI performed, N (%) | 7 11.4 4 15.4 3 8.6 | -                      | -                  | 0.73    |
| MRI findings, N (%) |          |                        |                     | 0.41    |
| Normal           | 0 0 0 0 0 | -                      | -                  | -       |
| New ischemic stroke | 1 16.7 1c 25.0 0 0 | -                      | -                  | -       |
| Inflammatory lesions | 1 16.7 1d 25.0 0 0 | -                      | -                  | -       |
| Hydrocephalus    | 1 16.7 0 0 1 33.3 | -                      | -                  | -       |
| Atrophy          | 2 33.3 1 25.0 1 33.3 | -                      | -                  | -       |
| Other            | 2 33.3 1 25.0 1 33.3 | -                      | -                  | -       |
| EEG performed, N (%) | 12 19.7 2 7.7 10 28.6 | -                      | -                  | 0.04    |
| EEG findings, N (%) |          |                        |                     | 0.89    |
| Normal           | 0 0 0 0 0 | -                      | -                  | -       |
| FIRDA            | 5 41.7 1 50 4 40 | -                      | -                  | -       |
| Sharp waves      | 1 8.3 0 0 1 10 | -                      | -                  | -       |
| Encephalopathic curve | 6 50 1 50 5 50 | -                      | -                  | -       |
| Epileptic activity | 0 0 0 0 0 | -                      | -                  | -       |
| LP performed, N (%) | 8 13.1 3 11.5 5 14.3 | -                      | -                  | 0.72    |
| CSF findings, N (%) |          |                        |                     | 0.19    |
| Normal cell count | 5 62.5 1 33.3 4 80 | -                      | -                  | -       |
| CSF pleocytosis (> 5 cells/microl) | 3 37.5 2c,d 66.6 1e 20 | -                      | -                  | -       |
| Cell levels (E6/L), median (IQR) | 3 2.5–69 125 1–271 3 3–3 | 0.53 0.37–0.86 0.59 0.43–1.13 0.49 0.3–0.56 | 0.46 |
| Protein levels (g/L), median (IQR) | 0.53 0.37–0.86 0.59 0.43–1.13 0.49 0.3–0.56 | 0.46 |
| SARS-CoV-2 CSF PCR test (positive) | 5 0 2 0 3 0 | -                      | -                  | -       |
| SARS-CoV-2 CSF Ab test (positive) | 1 1 1 1 0 0 | -                      | -                  | -       |
| ENG/EMG performed, N (%) | 1 1.6 0 0 1 2.9 | -                      | -                  | 0.38    |
| ENG/EMG findings, N (%) |          |                        |                     | -       |
| Critical illness myopathy | 1 100 0 0 1 100 | -                      | -                  | -       |

Paraclinical findings of COVID-19 positive patients dichotomized ICU and non-ICU patients

Ab antibody, ICU Intensive care unit, CT computed tomography, MRI magnetic resonance imaging, EEG electroencephalogram, LP lumbar puncture, ENG electroneurography, EMG electromyography, VZV varicella zoster virus

a For categorical values we tested with Fisher’s exact test for p value
b Patient initially admitted with cerebellar ICH. COVID-19 infection during hospitalization
c One patient with multiple strokes, CSF pleocytosis and severe encephalopathy (see Fig. 2 for case and images)
d Patient with transverse myelitis seen on spinal MRI and with CSF pleocytosis (see Fig. 2 for case and images)
e Severe headache and signs of CNS infection at admission. Positive VZV IgG antibodies in CSF (but negative VZV PCR) and pleocytosis with 13 cells
Negative. Long-term follow-up is needed to determine the risk for recurrence.

Neuromuscular complications

Eight of our patients had hypotonic tetraparesis with hyporeflexia and muscle atrophy. Unfortunately, owing to lockdown measures to prevent the spread of SARS-CoV-2, only one patient was investigated with nerve conduction studies which were consistent with CIPM. All 8 patients had prolonged admissions to the ICU, sepsis and multi-organ failure, resembling typical ICU-acquired weakness [34]. Previous studies on PNS complications in COVID-19 have mainly focused on Guillain–Barre syndrome [35] which we did not observe, even though our center is the referral center for GBS cases in the Greater Copenhagen area with 1.9 million inhabitants. We did, however, observe one case of rhabdomyolysis as a presenting complication of COVID-19, and myalgia with elevated CK in COVID-19 has indeed been previously reported [35]. Our patient with rhabdomyolysis and acute myopathy had no obvious cause for muscle injury other than COVID-19, but we were unable to obtain

Table 6  Diagnoses based on complications during admission and after 3 months

| Cerebrovascular, N (%) | All, N=61 | During admission, N=61 | After discharge, N=45 |
|------------------------|-----------|------------------------|----------------------|
|                        | N         | %          | N         | %          | N         | %          |
| Stroke, any type       | 4         | 6.6        | 2         | 3.3        | 2         | 4.4        |
| Ischemic               | 4         | 100        | 2         | 100        | 2         | 100        |
| Hemorrhagic            | 0         | 0          | 0         | 0          | 0         | 0          |
| Central nervous system, N (%) |          |            |          |            |          |            |
| Encephalopathy, any    | 19        | 31.1       | 19        | 31.1       | 1e        | 2.2        |
| Mild encephalopathy    | 6         | 31.6       | 6         | 31.6       | 0         | -          |
| Severe encephalopathy  | 13        | 68.4       | 13        | 68.4       | 1e        | -          |
| Severe encephalopathy with akinetic mutism | 8 | 42.1 | 8 | 42.1 | 0 | - |
| Encephalitis           | 2h,c      | -          | 2         | -          | 0         | -          |
| Myelitis               | 1d        | -          | 0         | -          | 1         | -          |
| Other                  | 1f        | -          | 0         | -          | 1f        | -          |
| Peripheral nervous system, N (%) |          |            |          |            |          |            |
| Neuropathy, any        | 12        | 19.7       | 8         | 13.1       | 4         | 8.9        |
| Peripheral facial palsy| 2         | 16.7       | 0         | 0          | 2         | 50         |
| Meralgia paresthetica  | 2         | 16.7       | 0         | 0          | 2         | 50         |
| CIPM, definite         | 1         | 8.3        | 1         | 8.3        | 0         | 0          |
| CIPM, possible         | 7         | 58.3       | 7         | 58.3       | 0         | 0          |
| Guillain Barre syndrome| 0         | 0.0        | 0         | 0          | 0         | 0          |
| Acute myopathy, any    | 1         | 8.3        | 1         | 8.3        | 0         | 0          |
| Other                  | 1g        | 8.3        | 0         | 0          | 1g        | 2.2        |

Cerebrovascular, Central and peripheral nervous system complications during admission and after discharge of COVID-19 positive patients

CIPM critical illness poly-neuropathy or myopathy

*One patient may have more than one complication

b Acute Hemorrhagic Necrotizing Encephalopathy (see Fig. 2 for image and case)

c One patient with severe apathy and amnesia without focal deficits, multiple ischemic lesions on MRI and CSF pleocytosis (see Fig. 2 for image and case)

d Patient with transverse myelitis seen on spinal MRI and with CSF pleocytosis

e One patient developed severe agitation, fits of screaming and automatisms with rocking back and forward. Psychiatric evaluation at nursing home without explanation. Treated with pregabalin that calmed the symptoms. The patient did also develop severe encephalopathy during admission. Lumbar puncture with normal cell and protein levels

f Admitted from a training facility with recurrent generalized seizures. CT of the brain and CSF investigation with normal findings. Severe hypomagnesemia due to possible refeeding syndrome

g Weeks after discharge, one patient developed right-sided drop foot, facial palsy, mild dysphagia and hypoglossal palsy. MRI normal, ENG with bilateral mild peroneal affection without specification. Symptoms resolved spontaneously
a muscle biopsy to determine if there were signs of direct viral invasion or inflammatory cell infiltrates.

Two of our patients were diagnosed with meralgia paresthetica, which has been reported as a complication following mechanical ventilation in the prone position in non-COVID-19 [36] and in COVID-19 patients [37]. As prone positioning in acute respiratory distress syndrome (ARDS) is strongly recommended [38] (and was performed in 61.7% of our ICU population), attention to peripheral nerve injury in COVID-19 ICU survivors seems warranted [39].

Further 2 patients developed a peripheral facial palsy after discharge. One patient had a concomitant VZV infection affecting the neck which was felt to be the most probable underlying etiology of the peripheral facial palsy, while the second patient had no plausible cause other than a recent SARS-CoV-2 infection. Unfortunately, the patients’ CSF samples were not tested for SARS-CoV-2 RNA. In a case series of 8 patients with COVID-19-associated peripheral facial palsy, all CSF studies were without inflammation (as in our cases), and 5 had PCR testing for SARS-CoV-2 in the CSF with negative results in all [40].

Methodological considerations

Besides prospectively screening for CNS and PNS symptoms during admission and at discharge, we adapted a case definition approach [7] to categorize complications into distinctive groups of suspected disease mechanisms. The vast majority (83%) was categorized as ‘complications secondary to critical illness, management-related or other causes’; much fewer complications were categorized as ‘indirect immune-mediated’ (7.3%); and none were categorized as “direct viral invasion”. A case definition approach has the benefit of attributing neurological disease to COVID-19 only when extensive laboratory investigations have been performed and other known causes have been excluded. This is important to avoid falsely assigning symptoms and signs to COVID-19 when in fact there is unrelated pathology: We encountered a remarkable patient who was diagnosed as having cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) prompted by typical neuroimaging features, including bilateral anterior temporal lobe FLAIR hyperintensities, on MRI performed for prolonged encephalopathy following COVID-19 (online appendix, Fig. S2). We did not include this patient in our prospective cohort because she presented to us several months after COVID-19. A similar case of CADASIL diagnosed in a COVID-19 patient owing to unsuspected MRI features has recently been described [41].

Our study has several other strengths: We evaluated a complete and consecutive sample of patients from a tertiary care center with detailed clinical characteristics, and we did not restrict inclusion to patients with a priori neurological presentations but enrolled all patients admitted, irrespective of their clinical symptoms. We distinguished between symptoms, investigations and clinical diagnoses. Unlike retrospective studies that depend on correct EHR coding for data extraction [1-4], we examined patients systematically and prospectively during the entire hospital stay and at discharge, thereby reducing the likelihood for underestimation of CNS and PNS complications. Like our study, a recent large prospective study [15] reported on pre-specified diagnoses but, unlike ours, its data were extracted from chart review of notes provided during neurology hospital consultation service. In our experience, not all patients are referred for neurologist consultation but are managed by anesthesiologists and infectious disease specialists instead, which probably leads to care providers overlooking neurological complications to some degree.

As to limitations, our cohort size was small, owing to the comparatively low burden of COVID-19 in the general population in Denmark in early 2020 [42], and patients were highly selected as ours is a tertiary referral center, which limits the generalizability of our findings. Also, during the pandemic, not all patients were investigated as thoroughly as usual, e.g. due to the widespread use of anticoagulation, which is a contraindication to lumbar puncture, CSF analysis was performed only in a subset of patients. Further, we might have underestimated the frequency of new-onset neurological and psychiatric manifestations at 3 months because we did not investigate patients without new contacts with the health care system after hospital discharge; and finally, we did not include a control group of non-COVID-19 patients. Future case-control studies are necessary to determine if SARS-CoV-2 infections are causal or coincidental and if complications are indeed more prevalent in COVID-19 patients compared to non-COVID-19 patients.

Conclusion

Neurological complications are common in hospitalized COVID-19 patients, occur mainly in severely affected patients in the ICU and can often be attributed to critical illness. In cases in which neurological disease was likely directly associated with COVID-19, we did not find signs of viral invasion of SARS-CoV-2 into the CNS or PNS, but laboratory inflammatory changes suggested autoimmune-mediated para- and post-infectious mechanisms. In this consecutive sample of 61 COVID-19 patients admitted to a tertiary hospital, the most common CNS and PNS complications were encephalopathy and CIPM, respectively, while other specific neurological presentations included akinetic mutism, acute necrotizing encephalopathy, transverse myelitis (autoimmune-mediated, CNS), and meralgia paresthetica (treatment-related, PNS).
A 52-year-old woman was admitted with convulsive seizures and reduced consciousness 19 days after symptom onset with dry cough, fever, a sore throat, headache and myalgias. Three weeks prior to presentation her entire family had experienced flu-like symptoms and a family member was tested positive for SARS-CoV-2. Previous medical history included hypertension, heterozygous Factor V Leiden mutation and chronic tension type headache. Medication before admission included amlopidine and gabapentin. On the morning of admission, the patient had generalized convulsive seizures. On examination, right-sided eye deviation and aphasias were noted. Twenty-four hours after admission, owing to a sudden decrease in consciousness and progressive hypoxic respiratory failure, the patient was intubated and transferred to the ICU. Chest X-ray revealed a complete white-out of the left lung. Microscopic examination of the bronchoalveolar lavage fluid revealed no microorganisms, and the fluid was negative with broad infectious workup, including negative culture and negative tests for SARS-CoV-2, influenza virus type A and B, adenovirus, metapneumovirus, parainfluenza virus, atypical pneumonia, mycobacteria, pneumocystis, fungi and CMV, except for a positive aspergillus galactomannan antigen. Cytologic examination of the lung biopsy revealed type II pneumocyte hyperplasia and capillary inflammation with macrophages and neutrophils. No hyaline membranes, granulomas, necrosis, fibrosis or vasculitis were observed. There was no microscopic evidence of malignancy or fungi, including immunohistochemical (IHC) staining for fungi. In the alveoli, there were small precipitations of fibrin. The findings were concluded to be unspecific, resembling findings observed in viral infection. Assays for antinuclear antibodies, anti-double-stranded DNA and rheumatoid factor were negative. Lupus anticoagulant and anticardiolipin antibodies were negative. Electroencephalography revealed generalized slowing, with no epileptiform activity. MRI of the brain with axial T2W (A1) and FLAIR (A2) sequences demonstrated bilateral hyperintense lesions in the right basal ganglia and left thalamus. Axial SWI images (A3) demonstrated hemorrhage, seen as hypointense signal intensity in the right basal ganglia lesion and venous system. Microbleeds were seen in the left thalamic lesion (A3) and ring enhancement on the post contrast T1W images (A4). A lumbar puncture was performed. Gram’s staining of the cerebrospinal fluid (CSF) showed no cells or organisms. The white-cell count was 0 per microliter (reference range, <5), the red-cell count was 0 per microliter (reference range, <300), the glucose level was 4.4 mmol per liter (2.2–3.9 mmol per liter), and the protein level was 0.3 g per liter (reference value, 0.15–0.50). Cytologic examination of the CSF revealed no malignant cells, and there was no evidence of B- of T-cell lymphoproliferative disorder on flow cytometry. Polymerase-chain-reaction assays of the CSF for herpes simplex virus and VZV were negative, as were mycobacterial smear and culture of the CSF. Culture of the CSF showed no growth. Testing of the CSF for autoantibodies, Lyme disease, syphilis, human herpes virus and SARS-CoV-2 were negative. Whole-body positron-emission tomography and computed tomography (PET-CT), performed after the administration of intravenous 18F-fluorodeoxyglucose (FDG) tracer, revealed no extracranial malignant disease. The differential diagnosis consisted of cerebral abscess or malignant tumor, and the patient was transferred to the neuro-interventional unit for further evaluation and treatment. To obtain a neuropathological diagnosis, stereotactic biopsy of the cerebral lesions was performed (A5-7). Biopsy specimens from both right and left cerebral hemispheres showed thrombotic occlusion of small vessels by fibrin thrombi. The brain parenchyma showed reactive changes with astroglisis and microgliosis, axonal swellings, proliferating capillaries and iron deposits (Perl’s stain) as sign of microbleeds. There were sparse diffuse lymphocytic infiltrates consisting of CD3 positive T- lymocytes. CD20 staining showed no B-lymphocytic infiltrates. There were no granulomas. There was no sign of demyelinating disease when comparing immunofluorescent immunostaining with myelin stains (LUXPAS and immunostaining for myelin basic protein). Immune staining’s for toxoplasma, herpes 1, cytomegalovirus and JC virus were all negative. There were no fungi or bacteria in special staining’s with PAS, Gomori and Gram. [Biopsy from the left cerebral hemisphere (A5) with thrombi and reactive changes (PAS staining). Fibrin thrombus in a small vessel (Masson trichrome staining) (A6). Higher magnification showing proliferating capillaries, hemosiderin in macrophages and gliosis (hematoxylin and eosin stain), (A7). Asterix: thrombus.] The team of neuropathologists concluded that the findings in the brain biopsy tissue were consistent with small necrotic lesions/infarctions, likely caused by fibrin thrombi in the vessels. The clinical suspicion of COVID-19 was confirmed by a positive serum test for SARS-CoV-2 showing high titers of neutralizing IgG-antibodies obtained on the 27th day of illness. A diagnosis of COVID-19-associated acute necrotizing encephalitis was made, based on clinical signs, MRI, brain pathology findings and high titers of SARS-CoV-2 IgG and exclusion of other causes following extensive diagnostic work-up. B1-B2. A 28-year-old woman with a previous medical history of hypothyroidism developed a dry cough and myalgia in the beginning of March and was tested SARS-CoV-2 positive 3 days later. COVID-19 symptoms lasted 6 days. Eight days after onset of COVID-19 symptoms, the patient developed lumbar back pain and progressive numbness in both legs with a mid-thoracic sensory level, impaired proprioception in the legs, absent abdominal reflexes and a slightly broad-based gait. Cognitive examination and the rest of the exam were unremarkable. Spinal MRI demonstrated on sagittal T1 STIR (B1) and sagittal T2 (B2) hyperintense lesions from C1 to C7 and from Th1 to the conus medullaris, consistent with transverse myelitis. Lumbar puncture showed a lymphocytic pleocytosis of 125 cells/microl, protein levels of 0.59 g/L, with a negative microbiological CSF work-up including herpes simplex virus, varicella zoster virus, cytomegalovirus, enterovirus, and SARS-CoV-2. Blood was negative for HIV and syphilis. Screening for aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies was negative. The patient was treated with high-dose prednisone and plasma exchange and made an uneventful recovery. Eight months later, the patient had a mild degree of Lhermitte’s but no other complaints. C1-C4. A 61-year-old woman with a previous medical history of type 2 diabetes, hypothyroidism and kidney transplant in 2019 due to adult onset polycystic kidney disease and immunosuppression with ciclosporine, developed muscle ache, dry cough, fever and dizziness resulting in a positive SARS-CoV-2 pharyngeal swab test and admission for 6 days. Eleven days after COVID-19 symptom onset, the patient developed headache, progressive confusion, apathy and speech difficulties and was re-admitted. Neurological examination revealed the patient was apractic, apathetic and amnestic. She answered questions with latency and with a mild, non-fluent aphasic speech. Brain MRI demonstrated bilateral hyperintense lesions in the basal ganglia on axial T2 (C1), FLAIR (C2) and DWI (C3), with corresponding hypointense lesions on ADC (C4). Lumbar puncture showed a lymphocytic pleocytosis of 252 cells (E6/L), protein levels of 1.77 g/L. CSF microscopy was unremarkable, and cultures for bacteria and fungi were negative. CSF screening for E.coli., Hemophilus influenzae, listeria, neisseria, streptococcus, enterovirus, Cryptococcus neoformans, syphilis (both intrathecal and peripheral testing), Lyme’s disease, JC virus, 18S-RNA, flow cytometry, and LG1, NMDA, GABA-B, and CASPR2 antibody screening for autoimmune encephalitis were all negative. HIV and hepatitis B testing, tranesopahageal echocardiography, whole-body FDG-PET for occult malignancy were also unremarkable. There were a positive PCR and intrathecal antibody titer for EBV, HSV-1, VZV and human herpes virus, but the attending infectious disease and microbiology colleagues considered this to be consistent with a reactive phenomenon owing to chronic immunosuppression. The patient was initially treated with ceftriaxone and azacylovir, but treatment was stopped after a few days when no clear evidence of bacterial or herpes virus encephalitis was found. The patient made a gradual and spontaneous recovery, but cognitive impairment of memory and executive function remained after discharge.
As stated above, need for consent to participate was waived because the risks were deemed negligible (reference j.nr. 20025838). The Ethics Committee of the Capital Region of Denmark approved the study and waived the need for written consent. The authors declare that they have no conflicts of interest. Anonymized data is available for all study patients and will be shared by reasonable request from any qualified investigator.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflicts of interest.

Ethics approval The Ethics Committee of the Capital Region of Denmark approved the study and waived the need for written consent because the risks were deemed negligible (reference j.nr. 20025838).

Consent to participate As stated above, need for consent to participation was waived by the Danish Ethics Committee. No patient-identifying images have been included.

Consent to publication The authors consent to the publication of this manuscript. This manuscript has not been published elsewhere and is not under consideration by another journal. We have uploaded it to medRxiv.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Helms J, Kremer S, Merdji H et al (2020) Neurologic features in severe SARS-CoV-2 infection. N Engl J Med 382:2268–2270. https://doi.org/10.1056/nejmc2008597
2. Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E et al (2020) Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry. Neurology 95:e1060–e1070. https://doi.org/10.1212/WNL.0000000000009937
3. Xiong W, Mu J, Guo J et al (2020) New onset neurologic events in people with COVID-19 in 3 regions in China. Neurology 95:e1479–e1487. https://doi.org/10.1212/WNL.00000000000030034
4. Mao L, Jin H, Wang M et al (2020) Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan. JAMA Neurol, China. https://doi.org/10.1001/jamaneurrol.2020.1127
5. Karadag Ö, Öztürk B, Sonkaya AR (2020) A prospective clinical study of detailed neurological manifestations in patients with COVID-19. Neurol Sci 41:1991–1995. https://doi.org/10.1007/s10072-020-04547-7
6. Pinna P, Grewal P, Hall JP et al (2020) Neurological manifestations and COVID-19: experiences from a tertiary care center at the Frontline. J Neurol Sci. https://doi.org/10.1016/j.jns.2020.116969
7. Ellul MA, Benjamin L, Singh B et al (2020) Neurological associations of COVID-19. Lancet Neurol 19:767–783
8. Pezzi A, Padovani A (2020) Lifting the mask on neurological manifestations of COVID-19. Nat Rev Neurol 16:636–644. https://doi.org/10.1038/s41582-020-0398-3
9. Solomon IH, Normandin E, Bhattacharyya S et al (2020) Neuropathological features of Covid-19. N Engl J Med 383:989–992. https://doi.org/10.1056/nejmc2019373
10. Matschke J, Lütgehetmann M, Hagel C et al (2020) Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol 19:919–929. https://doi.org/10.1016/s1474-4422(20)30308-2
11. Moriguchi T, Harri N, Goto J et al (2020) A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis 94:55–58. https://doi.org/10.1016/j.ijid.2020.03.062
12. Domingues RB, Mendes-Correia MC, de Moura Leite FBV et al (2020) First case of SARS-COV-2 sequencing in cerebrospinal fluid of a patient with suspected demyelinating disease. J Neurol 267(11):3154–3156
13. Gofton TE, Bryan Young G (2012) Sepsis-associated encephalopathy. Nat Rev Neurol 8:557–566
14. Axer H, Grimm A, Pausch C et al (2016) The impairment of small nerve fibers in severe sepsis and septic shock. Crit Care. https://doi.10.1186/s13054-016-1241-5
15. Frontera JA, Sabadía S, Lalchan R et al (2020) A Prospective study of neurologic disorders in hospitalized COVID-19 patients in New York city. Neurology. https://doi.org/10.1212/WNL.00000000000010979
16. Tsivgoulis G, Palaiodimou L, Katsanos AH et al (2020) Neurological manifestations and implications of COVID-19 pandemic. Ther Adv Neurol Disord 13:175628642093203
17. Woo BKP, Rice VA, Legendre SA et al (2004) The clock drawing test as a measure of executive dysfunction in elderly depressed patients. J Geriatr Psychiatry Neurol 17:190–194
18. Slooter AJC, Otte WM, Devlin JW et al (2020) Updated nomenclature of delirium and acute encephalopathy: statement of ten Societies. Intensive Care Med 46:1020–1022. https://doi.org/10.1007/s00134-019-05807-4
19. Venkatesan A, Tunkel AR, Bloch KC et al (2013) Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium. Clin Infect Dis 57:1114–1128. https://doi.org/10.1093/cid/cit458
20. Nance JR, Mammen AL (2015) Diagnostic evaluation of rhabdomyolysis. Muscle Nerve 51:793–810
21. Paterson RW, Brown RL, Benjamin L et al (2020) The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain. https://doi.org/10.1093/brain/awaa240
22. Cani I, Barone V, D’Angelo R et al (2020) Frontal encephalopathy related to hyperinflammation in COVID-19. J Neurol 1:1–4: https://doi.org/10.1007/s00415-020-10057-5 (Online ahead of print)
23. Delorme C, Paccoud O, Kas A et al (2020) COVID-19-related encephalopathy: a case series with brain FDG-poisiton-emission tomography/computed tomography findings. Eur J Neurol 27:2651–2657. https://doi.org/10.1111/ene.14478
24. Arnts H, van Erp WS, Lavrijsen ICM et al (2020) On the pathophysiology and treatment of akinetic mutism. Neurosci Biobehav Rev 112:270–278
25. Morandi A, Di Santo SG, Cherubini A et al (2017) Clinical features associated with delirium motor subtypes in older inpatients:
